Bio­gen shares rock­et up as My­lan's chal­lenge to Tec­fidera patents is slapped down

Bio­gen $BI­IB just won one of the biggest fights it’s ever faced.

The big biotech beat My­lan’s chal­lenge on the patents that guard their cash cow, Tec­fidera, the mul­ti­ple scle­ro­sis drug that drove the com­pa­ny’s come­back un­der George Scan­gos and sus­tains his suc­ces­sor Michel Vounatsos as they search for new drugs.

In the in­ter partes re­view rul­ing, the Patent Tri­al and Ap­peal Board — or PT­AB — de­ter­mined:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER